Marla Weetall

4.7k total citations
70 papers, 1.2k citations indexed

About

Marla Weetall is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Marla Weetall has authored 70 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 14 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Marla Weetall's work include RNA modifications and cancer (10 papers), Biochemical and Molecular Research (9 papers) and Cancer Cells and Metastasis (6 papers). Marla Weetall is often cited by papers focused on RNA modifications and cancer (10 papers), Biochemical and Molecular Research (9 papers) and Cancer Cells and Metastasis (6 papers). Marla Weetall collaborates with scholars based in United States, Switzerland and Japan. Marla Weetall's co-authors include Thomas W. Davis, Josephine Sheedy, David Holowka, Barbara Baird, Liangxian Cao, Sergey Paushkin, Nikolai A. Naryshkin, Hasane Ratni, Ellen Welch and Frank P. Buxton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Marla Weetall

68 papers receiving 1.2k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Marla Weetall 795 233 164 154 142 70 1.2k
Vanessa Baeriswyl 728 0.9× 84 0.4× 452 2.8× 150 1.0× 158 1.1× 14 1.1k
Eric G. Bremer 814 1.0× 85 0.4× 172 1.0× 394 2.6× 137 1.0× 19 1.5k
Gregory J. Riggins 1.0k 1.3× 182 0.8× 432 2.6× 116 0.8× 66 0.5× 35 1.9k
Anatol Oleksijew 634 0.8× 127 0.5× 339 2.1× 94 0.6× 86 0.6× 22 1.0k
Rajkumar Ganesan 618 0.8× 76 0.3× 321 2.0× 400 2.6× 219 1.5× 37 1.3k
Bo‐Sheng Pan 1.1k 1.4× 75 0.3× 290 1.8× 206 1.3× 40 0.3× 16 1.6k
Maureen H. Beresini 560 0.7× 41 0.2× 200 1.2× 137 0.9× 135 1.0× 34 1.2k
István Peták 1.1k 1.4× 176 0.8× 647 3.9× 247 1.6× 70 0.5× 61 1.8k
Michelle L. Kraus 466 0.6× 68 0.3× 447 2.7× 101 0.7× 63 0.4× 9 1.1k
Julia Jellusova 615 0.8× 128 0.5× 168 1.0× 973 6.3× 122 0.9× 28 1.5k

Countries citing papers authored by Marla Weetall

Since Specialization
Citations

This map shows the geographic impact of Marla Weetall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marla Weetall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marla Weetall more than expected).

Fields of papers citing papers by Marla Weetall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marla Weetall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marla Weetall. The network helps show where Marla Weetall may publish in the future.

Co-authorship network of co-authors of Marla Weetall

This figure shows the co-authorship network connecting the top 25 collaborators of Marla Weetall. A scholar is included among the top collaborators of Marla Weetall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marla Weetall. Marla Weetall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tine, Brian A. Van, Matthew Ingham, Steven Attia, et al.. (2024). Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma. Journal of Clinical Oncology. 42(20). 2404–2414. 3 indexed citations
2.
Dey, Anindya, Shailendra Kumar Dhar Dwivedi, Lin Wang, et al.. (2022). Targeting BMI1 mitigates chemoresistance in ovarian cancer. Genes & Diseases. 9(6). 1415–1418. 1 indexed citations
3.
4.
Sagalovskiy, Irina R., H. Carlo Maurer, Stephen A. Sastra, et al.. (2019). Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 25(18). 5548–5560. 18 indexed citations
5.
Morini, Elisabetta, Dadi Gao, Monica Salani, et al.. (2019). ELP1 Splicing Correction Reverses Proprioceptive Sensory Loss in Familial Dysautonomia. The American Journal of Human Genetics. 104(4). 638–650. 26 indexed citations
6.
Barbosa, Karina, Anagha Deshpande, Bo-Rui Chen, et al.. (2019). Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1. Experimental Hematology. 74. 42–51.e3. 11 indexed citations
7.
Dey, Anindya, Shailendra Kumar Dhar Dwivedi, Kai Ding, et al.. (2018). Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Molecular Cancer Therapeutics. 17(10). 2136–2143. 14 indexed citations
8.
Poirier, Agnès, Marla Weetall, Katja Heinig, et al.. (2018). Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacology Research & Perspectives. 6(6). e00447–e00447. 114 indexed citations
9.
Poirier, Agnès, Marla Weetall, Hasane Ratni, et al.. (2018). Relationship Between Central and Peripheral SMN Protein Increase Upon Treatment with RO7034067 (RG7916) (S46.007). Neurology. 90(15_supplement). 1 indexed citations
10.
Bolomsky, Arnold, Roy Heusschen, Joséphine Muller, et al.. (2017). Preclinical Evaluation of the First in Class BMI1 Inhibitor PTC-028 Confirms Potent Efficacy to Target BMI1-Addiction in Multiple Myeloma. Blood. 130. 1804–1804. 1 indexed citations
11.
Cao, Liangxian, Arthur Branstrom, John D. Baird, et al.. (2017). PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells. Blood. 130. 1371–1371. 1 indexed citations
12.
Friesen, Westley J., Christopher R. Trotta, Jin Zhuo, et al.. (2017). The nucleoside analog clitocine is a potent and efficacious readthrough agent. RNA. 23(4). 567–577. 36 indexed citations
13.
Graci, Jason D., Guangming Chen, Gillian M. Schiralli Lester, et al.. (2017). Identification of benzazole compounds that induce HIV-1 transcription. PLoS ONE. 12(6). e0179100–e0179100. 2 indexed citations
14.
Shapiro, Geoffrey I., Jon Infante, Todd M. Bauer, et al.. (2016). Initial first-in-human phase 1 results of PTC596, a novel small molecule that targets cancer stem cells (CSCs) by reducing BMI1 protein levels. Annals of Oncology. 27. vi122–vi122. 2 indexed citations
15.
Zhang, Nanjing, Anthony Turpoff, Xiaoyan Zhang, et al.. (2015). Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B. Bioorganic & Medicinal Chemistry Letters. 26(2). 594–601. 10 indexed citations
16.
Chen, Guangming, Hongyu Ren, Anthony Turpoff, et al.. (2013). Discovery of N-(4′-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication. Bioorganic & Medicinal Chemistry Letters. 23(13). 3942–3946. 15 indexed citations
17.
Cao, Liangxian, et al.. (2011). BMI1 as a novel target for drug discovery in cancer. Journal of Cellular Biochemistry. 112(10). 2729–2741. 117 indexed citations
18.
19.
Wattanasin, Sompong, Beat Weidmann, Didier Roche, et al.. (2001). Design and Synthesis of Potent and Selective Inhibitors of Integrin VLA-4. Bioorganic & Medicinal Chemistry Letters. 11(22). 2955–2958. 11 indexed citations
20.
Weetall, Marla, Ronald J. Hugo, Susan West, et al.. (2001). A Homogeneous Fluorometric Assay for Measuring Cell Adhesion to Immobilized Ligand Using V-Well Microtiter Plates. Analytical Biochemistry. 293(2). 277–287. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vanessa Baeriswyl Breakdown of academic impact, for papers by Eric G. Bremer Breakdown of academic impact, for papers by Gregory J. Riggins Breakdown of academic impact, for papers by Anatol Oleksijew Breakdown of academic impact, for papers by Rajkumar Ganesan Breakdown of academic impact, for papers by Bo‐Sheng Pan Breakdown of academic impact, for papers by Maureen H. Beresini Breakdown of academic impact, for papers by István Peták Breakdown of academic impact, for papers by Michelle L. Kraus Breakdown of academic impact, for papers by Julia Jellusova
Rankless by CCL
2026